9 results
The objective of this study is to demonstrate (1) the superior efficacy of VTE prophylaxis with oral rivaroxaban 10 mg once daily administered for 35 ± 4 days to SC enoxaparin 40 mg once daily (OD) administered for 10 ± 4 days in men and women aged…
European registry of children and patients with congenital heart disease that undergo ICD or CRT implantation. This will lead to a larger amount of data leading to increased knowledge about long-term consequences and potential complications.
To demonstrate that oral apixaban 2.5 mg BID is superior to subcutaneous (SC)enoxaparin 40 mg QD in reducing the event rate on the composite endpoint of adjudicated asymptomatic and symptomatic DVT, non-fatal PE and all-cause death through Day 12 of…
To demonstrate that oral administration of apixaban 2.5 mg BID for 30 days reduces the rate of total venous thromboembolism (VTE) and VTE-related death compared to standard, subcutaneous administration of enoxaparin 40 mg QD for a recommended…
The primary efficacy objective is to evaluate whether LMWH is superior to VKAs in the long-term treatment of symptomatic VTE in cancer patients who completed 6 to 12 months of anticoagulant treatment. Two aspects are important: the efficacy with…
The purpose of this study is to evaluate the safety and effectiveness of the Aveir wireless dual-chamber pacemaker system in the treatment of patients with slow or irregular heartbeats.
Study aimsThe aim of the current study is to assess the effect of a nasal airway stent (Nastent R) as a treatment modality in patients with snoring and/or OSA. Hypothesis Nastent R, a distally perforated soft silicon nasal tube, is a mechanical…
Our objective is to study if reduced anticoagulation targets diminish bleeding complications without an increase in thromboembolic complications or a negative impact on outcome.
1. Primary objective: - SARS-CoV-2 binding (expressed as concentration of virus bound in pg/mL) to epithelial cells isolated from nasal cavity between intervention and control groups (every volunteer is his own control group, depending on nostril).…